10:21 , Aug 24, 2017 |  BC Innovations  |  Product R&D

MedImmune's neo stimulus package

The MedImmune LLC unit of AstraZeneca plc thinks its pipeline of immune stimulators will give it an edge in the crowded field of neoantigen cancer vaccines. The company's strategy raises the question of whether the...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Simplexa Group A Strep Direct regulatory update

FDA granted 510(k) clearance to Simplexa Group A Strep Direct Kit from Quest to detect Group A Streptococcus bacteria from throat swabs. The agency categorized it as a moderate complexity test. Quest said the real...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Amgen management update

Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif.   Business: Biopharmaceuticals   Hired: David Meline as EVP and CFO, effective July 21, formerly SVP and CFO of 3M Co.; he succeeds acting CFO Michael Kelly   ...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

BA058-transdermal: Phase II data

Top-line data from a double-blind, international Phase II trial in 250 postmenopausal women with osteoporosis showed that once-daily 50, 100 and 150 µg doses of transdermal abaloparatide applied to the skin and removed after 5...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

Adamis, 3M deal

Adamis said it made a $7 million final payment and completed its acquisition of exclusive, worldwide rights to use 3M's Taper Dry Powder Inhaler (DPI) technology in all indications in the dry powder inhalation field...
01:29 , Dec 14, 2013 |  BC Extra  |  Financial News

Adamis raises $22.1 million, moves to NASDAQ

Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) began trading on NASDAQ on Friday after raising $22.1 million through the sale of 3.7 million shares at $5.95 in a follow-on underwritten by CRT Capital and Newport Coast Securities. Adamis,...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

R343: Development discontinued

Rigel discontinued development of R343 after the double-blind, international Phase II SITAR trial in about 300 patients with mild to moderate allergic asthma showed that twice-daily inhaled R343 missed the primary endpoint of improving FEV1...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Adamis, 3M deal

Adamis will acquire exclusive, worldwide rights to use 3M's Taper Dry Powder Inhaler (DPI) technology in all indications in the dry powder inhalation field. Adamis plans to use the technology, which stores APIs on a...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Radius Health, 3M deal

Radius and 3M amended a 2011 deal to develop a transdermal formulation of BA058. Radius said the amendment covers exclusive development of bone anabolics, including parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP), for...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Clinical News

BA058-transdermal: Completed Phase II enrollment

Radius completed enrollment of 250 postmenopausal women with osteoporosis in a double-blind, placebo-controlled, international Phase II trial comparing 50, 100 and 150 µg BA058-TD once daily vs. once-daily 80 µg subcutaneous BA058-Injection ( BA058-SC) for...